Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
U.S. Federal Trade Commission
Pharma
Roche CEO critiques Novo's proposed Catalent buyout
Roche’s CEO critiqued Novo Holdings' Catalent buyout, arguing that the deal could hurt smaller drugmakers in need of manufacturing assistance.
Fraiser Kansteiner
Oct 23, 2024 12:35pm
Warren challenges Novo Holdings' proposed Catalent buyout
Oct 10, 2024 2:16pm
Catalent reports upbeat Q4 results as it awaits review of sale
Aug 30, 2024 9:30am
Former FTC director weighs in on $16.5B Novo-Catalent deal
Jul 19, 2024 9:27am
FTC launches investigation into Teva's inhaler patents: report
Jul 2, 2024 10:02am
What are the noncompete considerations in Caforio's next move?
Jul 1, 2024 12:02pm